Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-02-01

FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZUBSOLV (buprenorphine and naloxone) from Orexo US, Inc. This action updates the product's labeling per the approved…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZUBSOLV (Buprenorphine hydrochloride and naloxone hydrochloride)

Snippet

SUPPL AP for ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)